SK286256B6 - Biarylové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents
Biarylové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie Download PDFInfo
- Publication number
- SK286256B6 SK286256B6 SK1908-2000A SK19082000A SK286256B6 SK 286256 B6 SK286256 B6 SK 286256B6 SK 19082000 A SK19082000 A SK 19082000A SK 286256 B6 SK286256 B6 SK 286256B6
- Authority
- SK
- Slovakia
- Prior art keywords
- amino
- ethyl
- biphenyl
- chlorophenyl
- hydroxyethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9812709.5A GB9812709D0 (en) | 1998-06-13 | 1998-06-13 | Chemical compounds |
| PCT/EP1999/003958 WO1999065877A1 (en) | 1998-06-13 | 1999-06-09 | Therapeutic biaryl derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK19082000A3 SK19082000A3 (sk) | 2001-09-11 |
| SK286256B6 true SK286256B6 (sk) | 2008-06-06 |
Family
ID=10833658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1908-2000A SK286256B6 (sk) | 1998-06-13 | 1999-06-09 | Biarylové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6251925B1 (ru) |
| EP (1) | EP1087943B1 (ru) |
| JP (1) | JP3471754B2 (ru) |
| KR (1) | KR100415877B1 (ru) |
| CN (1) | CN1214008C (ru) |
| AP (1) | AP1687A (ru) |
| AR (1) | AR029301A1 (ru) |
| AT (1) | ATE302189T1 (ru) |
| AU (1) | AU753004B2 (ru) |
| BR (1) | BR9911182B1 (ru) |
| CA (1) | CA2334713C (ru) |
| CO (1) | CO5060482A1 (ru) |
| CZ (1) | CZ299172B6 (ru) |
| DE (1) | DE69926752T2 (ru) |
| DK (1) | DK1087943T3 (ru) |
| EA (1) | EA003641B1 (ru) |
| EE (1) | EE04435B1 (ru) |
| EG (1) | EG23856A (ru) |
| ES (1) | ES2245107T3 (ru) |
| GB (1) | GB9812709D0 (ru) |
| HK (1) | HK1034253A1 (ru) |
| HR (1) | HRP20000854B1 (ru) |
| HU (1) | HUP0102668A3 (ru) |
| ID (1) | ID27841A (ru) |
| IL (2) | IL140219A0 (ru) |
| IS (1) | IS2277B (ru) |
| MY (1) | MY119542A (ru) |
| NO (1) | NO318782B1 (ru) |
| NZ (1) | NZ508805A (ru) |
| PE (1) | PE20000726A1 (ru) |
| PL (1) | PL196943B1 (ru) |
| RS (1) | RS49921B (ru) |
| SI (1) | SI1087943T1 (ru) |
| SK (1) | SK286256B6 (ru) |
| TR (1) | TR200100299T2 (ru) |
| TW (1) | TWI244471B (ru) |
| WO (1) | WO1999065877A1 (ru) |
| ZA (1) | ZA200007417B (ru) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9929118D0 (en) * | 1999-12-10 | 2000-02-02 | Glaxo Group Ltd | Chemical compounds |
| GB9929297D0 (en) * | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
| DE10005150A1 (de) * | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
| IL154911A0 (en) | 2000-10-20 | 2003-10-31 | Pfizer Prod Inc | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| GB0102407D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
| US7034053B2 (en) | 2001-01-31 | 2006-04-25 | Smithkline Beecham Corporation | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors |
| GB0102408D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Chemical compounds |
| US7709677B2 (en) | 2001-01-31 | 2010-05-04 | Glaxosmithkline Llc | Process of preparing arylethanoldiamines |
| EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| EP1430043A1 (en) | 2001-09-14 | 2004-06-23 | Bayer Pharmaceuticals Corporation | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| CA2471646A1 (en) | 2002-02-27 | 2003-09-04 | Yong Tao | Processes and intermediates useful in preparing .beta.3-adrenergic receptor agonists |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| AU2003209527A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| DOP2003000587A (es) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
| WO2003072571A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist |
| AU2003248614B2 (en) * | 2002-07-17 | 2007-08-30 | Lek Pharmaceuticals D.D. | Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them |
| GB0220730D0 (en) * | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP4896518B2 (ja) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| DE602004014727D1 (de) | 2003-02-14 | 2008-08-14 | Kissei Pharmaceutical | Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon |
| CN100418944C (zh) * | 2003-02-14 | 2008-09-17 | 橘生药品工业株式会社 | 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用 |
| WO2005040093A1 (ja) * | 2003-10-24 | 2005-05-06 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| CN100582088C (zh) * | 2003-12-23 | 2010-01-20 | 安斯泰来制药有限公司 | 氨基醇衍生物 |
| US7915309B2 (en) * | 2007-06-20 | 2011-03-29 | Protia, Llc | Deuterium-enriched oseltamivir |
| US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| CA2807135C (en) | 2010-08-03 | 2019-05-14 | Altherx, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| SG11201404776PA (en) | 2012-02-09 | 2014-09-26 | Altherx Inc | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
| WO2014108449A1 (en) | 2013-01-08 | 2014-07-17 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| EP3226849A4 (en) | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| FI3365321T3 (fi) * | 2015-10-23 | 2024-01-02 | B3Ar Therapeutics Inc | Solabegron-Zwitterioni ja sen käyttöjä |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0006735B1 (en) * | 1978-06-28 | 1983-06-15 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
| DE3934436A1 (de) | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5061727A (en) * | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
| NO179246C (no) * | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
| AU2737295A (en) | 1994-06-09 | 1996-01-04 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
-
1998
- 1998-06-13 GB GBGB9812709.5A patent/GB9812709D0/en not_active Ceased
-
1999
- 1999-06-09 NZ NZ508805A patent/NZ508805A/en not_active IP Right Cessation
- 1999-06-09 AU AU45103/99A patent/AU753004B2/en not_active Expired
- 1999-06-09 RS YUP-792/00A patent/RS49921B/sr unknown
- 1999-06-09 CN CNB99809630XA patent/CN1214008C/zh not_active Expired - Lifetime
- 1999-06-09 AR ARP990102733A patent/AR029301A1/es active IP Right Grant
- 1999-06-09 IL IL14021999A patent/IL140219A0/xx active IP Right Grant
- 1999-06-09 CZ CZ20004648A patent/CZ299172B6/cs not_active IP Right Cessation
- 1999-06-09 KR KR10-2000-7014098A patent/KR100415877B1/ko not_active IP Right Cessation
- 1999-06-09 DE DE69926752T patent/DE69926752T2/de not_active Expired - Lifetime
- 1999-06-09 JP JP2000554704A patent/JP3471754B2/ja not_active Expired - Lifetime
- 1999-06-09 AP APAP/P/2001/002028A patent/AP1687A/en active
- 1999-06-09 SK SK1908-2000A patent/SK286256B6/sk not_active IP Right Cessation
- 1999-06-09 ES ES99927923T patent/ES2245107T3/es not_active Expired - Lifetime
- 1999-06-09 PL PL344865A patent/PL196943B1/pl unknown
- 1999-06-09 ID IDW20010101A patent/ID27841A/id unknown
- 1999-06-09 EP EP99927923A patent/EP1087943B1/en not_active Expired - Lifetime
- 1999-06-09 CA CA002334713A patent/CA2334713C/en not_active Expired - Lifetime
- 1999-06-09 WO PCT/EP1999/003958 patent/WO1999065877A1/en active IP Right Grant
- 1999-06-09 SI SI9930827T patent/SI1087943T1/sl unknown
- 1999-06-09 US US09/719,595 patent/US6251925B1/en not_active Expired - Lifetime
- 1999-06-09 EA EA200001172A patent/EA003641B1/ru not_active IP Right Cessation
- 1999-06-09 DK DK99927923T patent/DK1087943T3/da active
- 1999-06-09 HU HU0102668A patent/HUP0102668A3/hu unknown
- 1999-06-09 TR TR2001/00299T patent/TR200100299T2/xx unknown
- 1999-06-09 AT AT99927923T patent/ATE302189T1/de active
- 1999-06-09 CO CO99036228A patent/CO5060482A1/es unknown
- 1999-06-09 BR BRPI9911182-9A patent/BR9911182B1/pt not_active IP Right Cessation
- 1999-06-09 EE EEP200000744A patent/EE04435B1/xx not_active IP Right Cessation
- 1999-06-10 PE PE1999000517A patent/PE20000726A1/es not_active Application Discontinuation
- 1999-06-10 EG EG70199A patent/EG23856A/xx active
- 1999-06-10 MY MYPI99002368A patent/MY119542A/en unknown
- 1999-06-16 TW TW088110054A patent/TWI244471B/zh not_active IP Right Cessation
-
2000
- 2000-12-08 IS IS5760A patent/IS2277B/is unknown
- 2000-12-11 IL IL140219A patent/IL140219A/en not_active IP Right Cessation
- 2000-12-12 NO NO20006319A patent/NO318782B1/no not_active IP Right Cessation
- 2000-12-12 ZA ZA200007417A patent/ZA200007417B/en unknown
- 2000-12-13 HR HR20000854A patent/HRP20000854B1/xx not_active IP Right Cessation
-
2001
- 2001-07-11 HK HK01104848A patent/HK1034253A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK286256B6 (sk) | Biarylové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie | |
| NL1028948C2 (nl) | Ortho gesubstitueerde aryl- of heteroarylamideverbindingen. | |
| JP3507494B2 (ja) | タキキニン拮抗薬 | |
| KR100888001B1 (ko) | 카르복시산 유도체 및 그의 염 | |
| NL1028947C2 (nl) | Gesubstitueerde methylaryl- of heteroarylamideverbindingen. | |
| US7005538B1 (en) | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
| US7371777B2 (en) | Cyclic compound and PPAR agonist | |
| DE60216094T2 (de) | Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar) | |
| US8008315B2 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| JP2690006B2 (ja) | 糖尿病及び肥満の治療のための選択的β３作働薬としての置換フェニルスルホンアミド | |
| ZA200210207B (en) | N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives. | |
| US7319096B2 (en) | Thyroid hormone receptor antagonists for cardiac and metabolic disorders II | |
| JP2009514816A (ja) | 新規ベータ−アゴニスト、それらの調製方法及び薬物としてのそれらの使用 | |
| RU2169141C2 (ru) | Производные фенилалкилкарбоновой кислоты и фармацевтическая композиция на их основе | |
| US6537994B2 (en) | Heterocyclic β3 adrenergic receptor agonists | |
| JP3506714B2 (ja) | １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途 | |
| JP2001525399A (ja) | 選択的β３アドレナリン作動性作動薬 | |
| JP2004520346A (ja) | Ｌｄｌ受容体発現のインデューサーとしてのアリールピペリジン誘導体 | |
| EP0749957B1 (en) | Aromatic hydroxamic acid compounds, their production and use | |
| US6458817B1 (en) | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | |
| MXPA00012389A (en) | Therapeutic biaryl derivatives | |
| JP2000169449A (ja) | 含フッ素１，４―ジ置換ピペリジン誘導体の新規製造中間体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20160609 |